Hazard ratio = 0.92(95% CI 0.83 to 1.02)

p=0.12

Months of follow-up

0 363024181260

10

20

30 Placebo

Rosuvastatin 10 mg

No. at riskPlacebo 2497 2315 2156 2003 1851 1431 811Rosuvastatin 2514 2345 2207 2068 1932 1484 855

Per

cent

of p

atie

nts

with

prim

ary

endp

oint

Kjekshus et al. N Engl J Med 2007;357(22):2248-61.

CORONA - Primary EndpointThe combined endpoint of cardiovascular death or non-fatal MI or non-

fatal stroke (time to first event)

Months of follow-up

0 36302418126

Placebo

Rosuvastatin 10 mg

0

3

6

12

9

15

Hazard ratio = 0.84(95% CI 0.70 to 1.00)

p = 0.05

No. at riskPlacebo 2497 2315 2156 2003 1851 1431 811Rosuvastatin 2514 2345 2207 2068 1932 1484 855

Per

cent

of p

atie

nts

with

eve

nt

Kjekshus et al. N Engl J Med 2007;357(22):2248-61.

CORONA Atherosclerotic Events

Post- hoc analysis of the number fatal/non-fatal MI or stroke in the primary endpoint

p=0.01p=0.007 p<0.001

4,074

2,564

1,2991,510

3,694

2,193

1,109

1,501

0

1,000

2,000

3,000

4,000

Heart failureAll cause CV cause Non-CV cause

Placebo (n=2,497)

Rosuvastatin 10 mg (n=2,514)

Num

ber

of h

ospi

taliz

atio

ns

Kjekshus et al. N Engl J Med 2007;357(22):2248-61.

CORONA – Secondary Endpoints

Total number of hospitalizations

Discontinuation of study drug1 546 490Adverse event2 302 241Patient unwilling to continue 162 187Other reason 82 62

Placebo Rosuvastatin [n=2497] [n=2514]

no. of pts no. of pts

1Hazard ratio 0.88; (95% CI 0.78 to 0.99; p=0.03)2Hazard ratio 0.78; (95% CI 0.66 to 0.92; p=0.004)

Kjekshus et al. N Engl J Med 2007;357(22):2248-61.

CORONA – Side Effects and Adverse Events

Tolerability and safety data